Michael Davidson MD

My Interview at JPM on BioTech TV x.com/BiotechTV/stat…

buzzsprout.com/2508586/episod… Very proud of my former Lipidology Fellow Priya Vishnu. Priya is an accomplished writer and excels in explaining clinical concepts to improve patient care.

Serial CLEERLY scans provide reassurance to a young woman with FH and premature ASCVD that aggressive LDL-c reduction with a statin, ezetimibe and Repatha shows a decrease in non-calcified plaque volume and stabilization of stenoses. Interventional Lipidology is very rewarding!

@JoshJwageman The variant is rs750185173

@mdavidsonmd Fascinating case...curious as to the specific variant! Although a different pathophysiology, this makes me think of ApoA-1 Iowa! pmc.ncbi.nlm.nih.gov/articles/PMC49…

Lipid Case: 57 yo male with preclinical ASCVD ( LAD lesion 50%) with LDL 57mg/dl but LDL-p 1350 and HDL 51mg/dl and normal HDL-p but no large HDL-p. Genetic test reveals rare apoA1 variant which explains dysfunctional HDL, premature ASCVD and corneal arcus. HDL can matter!

Congratulations to Molly Altenburg MD, the 5th Reyes Prevention Fellow. I was blessed this year with her passion for patient care, enthusiasm for learning Lipidology, outstanding teaching and warm personality. Molly is graduating to lead the Prevention/Lipidology Center at Rush.

Saddened to hear the news of the passing of one of my hero's, Scott Grundy MD PhD. Scott was a pioneer in the burgeoning field of Lipidology, a influential researcher of both nutrition and pharmaceuticals, a great teacher and leader of the national cholesterol guidelines along with my good friend Neil Stone. Scott was also a kind and humble giant. His impact on the prevention of coronary artery disease is unequaled. May his memory be a blessing to all who loved him.

My first patient to start olezarsen ( anti-apoC3 ASO). She is LPL - Heterozygous but also has two ApoA5 SNPs. She has had at least 10 episodes of pancreatitis in the past 2 years and severe eruptive xanthomas despite weekly plasmapheresis. Hoping for a new lease on life!

Excited and proud of the Obicetrapib BROOKLYN trial in patients with HeFH as a late breaker at AHA. Thanks Steve Nicholls for an awesome presentation

My Lipid Legend Podcast on Healio. I enjoy working with my longterm friend Ron Corderio. healio.com/cme/mededtalks…

nytimes.com/2023/07/27/hea… This is the obituary in the NYT of the 117 year old women with the loss of function CETP variant identified in the Bronx Aging Study

@MattBMartin Rosuvastatin 10mg plus ezetimibe 10mg. She has some statin intolerance

@mdavidsonmd Intervention FTW! 👏

Before and after xanthoma regression in a patient with the Lebanese FH mutation. Interventional lipidology works much better than plastic surgery.

@hjluks Over the past two years

@mdavidsonmd Time course?

Thank you to the hundreds of patients and investigators across ten countries who participated in our Phase 3 BROOKLYN trial. Your support moves us closer to our goal of helping people at risk for cardiovascular disease. bit.ly/4fk9iSn

Thanks Tom! A little more background. He is a 58 yo male with a marked family history of premature ASCVD. On statins his LFTs increased significantly but have been stable on Rosuvastatin 5mg. Started Repatha 2.5 years ago and his LDL-c is 9mg/dl and HDL-c 74 mg/dl. Because of his family history including many members dying young from ASCVD he wanted serial CT angios mostly for a piece of mind. This is his second CLEERLY but he previously had multiple CT angios showing CHD progression. The CLEERLY results of 2.5+ of Repatha has for the first time provided some piece of mind that he may have a normal life expectancy.

Nice result Michael - and interesting to see the increased calcification. Was the patient also on statin therapy?

My first patient with serial CLEERLYs following two years of Repatha. With excellent control of LDL-C and a reduction in Lp(a) there is a marked decrease in non-calcified plaque volume and an increase in calcified plaque. The patient is happy and so is his interventional lipidologist.

The Prevention World lost a giant. George Bakris was the most prolific researcher, teacher and clinician in the history of hypertension. He will live on through his great work. I will remember him most as a great friend and colleague who was always eager to help with his amazing mind. May your memory be a blessing to all your many friends and family.

Two conferences, two continents, one growing team and one goal: To share new research on our investigational CETP inhibitor. Thank you to everyone at #NLASessions for another outstanding lipid-focused event.